checkAd

    EANS-Adhoc  508  0 Kommentare Marinomed Biotech AG: Greenshoe option fully exercised

    --------------------------------------------------------------------------------
    Disclosed inside information pursuant to article 17 Market Abuse Regulation
    (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
    The issuer is responsible for the content of this announcement.
    --------------------------------------------------------------------------------

    No Keyword
    28.02.2019

    Vienna - Vienna, 28 February 2019. Marinomed Biotech AG announces that the
    greenshoe option from the IPO of 39,000 shares at the offer price of EUR 75 per
    share was fully exercised. Erste Group Bank AG, acting as stabilising manager,
    has not conducted any stabilisation activities since the initial listing of the
    Marinomed shares on 1 February 2019.

    After exercising the greenshoe option and subject to the registration of the
    capital increase in the commercial register planned for next week, the share
    capital amounts to EUR 1,469,772, split into 1,469,772 voting shares, and the
    free float amounts to around 39%.

    About Marinomed Biotech AG
    Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
    development of innovative products derived from patent protected technology
    platforms to treat respiratory and ophthalmic conditions. The Carragelose®
    platform comprises innovative patent protected products targeting viral
    infections of the respiratory tract. Carragelose® is used in nasal sprays,
    throat sprays and lozenges, which are sold in more than 30 countries around the
    world in collaboration with international partners. The Marinosolv® technology
    platform increases the efficacy of hardly soluble compounds for the treatment of
    sensitive tissues such as the eyes and nose. Further information is available at
    www.marinomed.com [http://www.marinomed.com/].




    Further inquiry note:
    Eva Prieschl-Grassauer, PhD
    Chief Scientific Officer, Marinomed
    Veterinärplatz 1, 1210 Vienna, Austria
    Tel.: +43 (0)1 250 77 4460
    E-mail: eva.prieschl@marinomed.com
    http://www.marinomed.com

    Roland Mayrl
    Managing Partner, Metrum Communications
    Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
    Tel.: +43 (0) 1 504 69 87 331
    E-mail: r.mayrl@metrum.at
    http://www.metrum.at



    end of announcement euro adhoc
    --------------------------------------------------------------------------------

    issuer: Marinomed Biotech AG
    Veterinärplatz 1
    A-1210 Wien
    phone: 0043250774460
    FAX: 0043250774493
    mail: office@marinomed.com
    WWW: www.marinomed.com
    ISIN: ATMARINOMED6, AT0000A1WD52
    indexes:
    stockmarkets: Wien
    language: English






    news aktuell
    0 Follower
    Autor folgen

    Verfasst von news aktuell
    EANS-Adhoc Marinomed Biotech AG: Greenshoe option fully exercised - Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. - No Keyword 28.02.2019 …

    Schreibe Deinen Kommentar

    Disclaimer